The treatment landscape for MDS cancer entered a potentially transformative phase this week, as clinical and regulatory developments converged around a new promising therapy for higher-risk myelodysplastic syndromes (HR-MDS).
The approval of the global Phase 3 trial, named GLORA-4, for lisaftoclax (APG-2575) marks what many in the hematology community consider the most significant first-line trial in HR-MDS in decades. The oral BCL-2 inhibitor will be evaluated in combination with established therapy azacitidine, offering hope for patients who currently rely on hypomethylating agents or stem cell transplantation.
According to press materials, earlier-phase studies of the combination reported an overall response rate of approximately 75%, with acceptable tolerability. Investigators emphasize that lisaftoclax could become the first globally available targeted therapy for HR-MDS — a milestone that might reshape first-line care if final results confirm earlier signals.
Meanwhile, the biotech sector continues to push forward on multiple fronts. GT Biopharma, Inc. is advancing a novel immunotherapy candidate, GTB-3650, in its Phase 1 trial. The therapy aims to harness the body’s natural killer (NK) cells to target malignant bone-marrow clones, including those driving high-risk MDS. Early cohorts — three dosing levels — have concluded without major safety issues, clearing the path for dose escalation in Cohort 4.
Company commentary suggests that Cohort 4 may reach dosing levels more likely to trigger strong immune activation, potentially offering efficacy in otherwise refractory MDS cancer patients. If successful, GTB-3650 could pave the way for a new immunotherapy modality in MDS — a field historically dominated by cytotoxic and epigenetic drugs.
On another front, research into improving quality of life for lower-risk MDS (LR-MDS) patients continues to gather steam. Treatment for chronic anemia remains a major concern, as many LR-MDS patients depend on regular red blood cell transfusions. The investigational activin inhibitor elritercept is among the agents generating interest, with updated Phase 2 data scheduled for presentation at the upcoming American Society of Hematology Annual Meeting 2025 (ASH 2025).
If the data show durable improvements in hemoglobin levels and reduced transfusion dependence, elritercept could emerge as a valuable treatment for LR-MDS patients — especially those who have limited options beyond erythropoiesis-stimulating agents or supportive care.
Taken together, the simultaneous advancement of first-line targeted therapy, experimental immunotherapy, and novel supportive care for MDS cancer suggests a realignment in the field. While current standards such as hypomethylating agents and transplant remain valid, the horizon now includes treatments designed for better tolerability, molecular specificity, and improved quality of life.
Still, caution remains warranted. All these therapies remain investigational, and their long-term efficacy, durability, and safety remain to be proven. For patients—and for clinicians—the next 12–24 months will be critical in determining whether these promising developments translate into meaningful change.
Related topic：
